Will pirfenidone be included in medical insurance in 2024?

Pirfenidone is a pyridone compound with broad-spectrum anti-fibrotic effects. Pirfenidone has been proven to have significant efficacy in the treatment of idiopathic pulmonary fibrosis through repeated, randomized, placebo-controlled phase III clinical trials, and is the first drug to receive this certification.

Its pharmacological effect is mainly reflected in inhibiting the biological activity of fibroblasts, reducing cell proliferation and matrix collagen synthesis by regulating or inhibiting certain factors, thereby preventing and reversing fibrosis and scar formation. In addition, pirfenidone also has anti-inflammatory and antioxidant functions, which can effectively reduce the secretion of inflammatory mediators, reduce lipid peroxidation, and provide protection for tissue cells.

In clinical practice, pirfenidone is not only used to treat idiopathic pulmonary fibrosis, but also widely used in the treatment of renal interstitial fibrosis, liver fibrosis and other diseases. The method of taking it is relatively simple. The usual initial dose is 200 mg three times a day. Later, based on the patient's tolerance and clinical response, the dose can be adjusted to 600 mg three times a day.

However, it is worth noting that although pirfenidone is effective, it may also cause some side effects, such as gastrointestinal reactions and liver function damage. Therefore, it is necessary to strictly follow medical instructions during use and undergo regular physical examinations to ensure safety. Overall, pirfenidone is an outstanding drug in anti-fibrotic treatment, bringing new treatment options to many patients.

The domestic version of pirfenidone is already on the shelves in the Chinese market and will be covered by Class B medical insurance in 2024. For its specifications of 200 mg and 63 tablets, after medical insurance reimbursement, individual consumers only need to pay about 1,500 yuan. In addition, in India, consumers can also choose generic versions of pirfenidone, especially the 200mg 150-tablet version produced by the Indian company Cipla, which is priced at only about 650 yuan, which is very affordable. If you have more questions about pirfenidone, it is recommended to consult overseas medical experts for detailed answers.